|
Priyanka's Biotech Briefing
Ionis secured $30 million from Recordati for ex-U.S. rights to zilganersen, while FDA scrutiny grows over generative AI devices and CStone tapped Arrotex for sugemalimab commercialization.
The top 10 stories from Thu Jun 25, 2026 07:05 AM to Fri Jun 26, 2026 07:06 AM
Generated June 26, 2026 at 7:06 AM
|
|
|
#1 Actio Biosciences has a precision medicine approach to rare diseases - promising preclinical data in a genetically defined epilepsy has them eagerly awaiting forthcoming clinical results Published 2026-06-26 Actio Biosciences’ CEO said limited access to medicines for rare genetic diseases drove its development efforts, and the company’s KCNT-1 program is in clinic after preclinical efficacy results. Covered by: biotechtv.com |
#2 Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy Published 2026-06-25 Fosun Pharma co-president Xinli Wang said the company used two recent deals to rapidly expand its Alzheimer’s disease portfolio and build independent U.S. capabilities. Covered by: fiercebiotech.com |
#3 Two Claudin 18.2 ADCs Enter Final Stretch Of Global Race With China NDA Published 2026-06-25 Two anti-Claudin 18.2 antibody-drug conjugates are approaching potential world-first approvals in China, with final regulatory steps underway. Covered by: insights.citeline.com |
#4 Ionis bags $30M from Recordati for ex-US rights to near-approval rare disease prospect Published 2026-06-25 Ionis Pharmaceuticals received a $30 million upfront payment from Recordati after transferring ex-U.S. regional rights to zilganersen, a near-approval rare disease drug candidate. Covered by: fiercebiotech.com, endpoints.news |
#5 BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space Published 2026-06-25 AltruBio CEO Judy Chou said the company’s second-generation PSGL-1 antibody targets a T-cell checkpoint and discussed its ongoing UC clinical program and potential collaboration talks in I&I. Covered by: biotechtv.com |
#6 BIO Notebook: More US FDA Wordplay, Big Pharma Helps Entrances, Biotech M&A Offers Exits Published 2026-06-25 The final day of the BIO International Convention featured discussions on US FDA-related regulatory language, Big Pharma’s role in supporting biotech events, and biotech M&A activity. Covered by: insights.citeline.com |
#7 CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand Published 2026-06-25 CStone Pharmaceuticals appointed Arrotex to handle registration, market access, and commercialization of sugemalimab in Australia and New Zealand under an exclusive agreement. Covered by: prnewswire.com |
#8 STAT+: FDA’s breakthrough pipeline fills up with generative AI devices Published 2026-06-25 STAT reports FDA’s device pipeline is increasingly filled with generative AI products, raising questions about how low-risk medical devices and wellness technologies are regulated. Covered by: statnews.com |
#9 Automating Clinical Decisions For Healthcare System Efficiencies Published 2026-06-26 A persistent gap remains between computer science research and clinical practice, limiting the translation of research advances into routine healthcare decision-making. Covered by: insights.citeline.com |
#10 Tryngolza expansion gives Ionis its first prevalent-market test Published 2026-06-25 FDA approval of Tryngolza expands its use from rare familial chylomicronemia syndrome to severe hypertriglyceridemia, marking Ionis’s first broad cardiometabolic market test. Covered by: biocentury.com |
